Related Experiment Video

Updated: Jun 3, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Zoledronic acid for adjuvant use in patients with breast cancer

Sigrun Ressler1, Brigitte Mlineritsch, Richard Greil

  • 13rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory of Immunological and Molecular Cancer Research, Private Medical University Hospital, Salzburg, Austria.

Expert Review of Anticancer Therapy
|March 23, 2011
PubMed

Insights

Zoledronic acid prevents bone loss from breast cancer treatments. This bisphosphonate may also offer anticancer benefits in estrogen-deprived states, but long-term effects require consideration.

Area of Science:

  • Oncology
  • Pharmacology
  • Bone Metabolism

Background:

  • Zoledronic acid is a nitrogen-containing bisphosphonate used for metastatic bone disease.
  • It inhibits farnesyl diphosphonate synthase, reducing osteoclast activity.
  • Preclinical studies suggest zoledronic acid has anti-tumor effects in breast cancer.

Purpose of the Study:

  • To evaluate zoledronic acid's efficacy in preventing bone loss associated with adjuvant endocrine therapy for breast cancer.
  • To explore potential anticancer effects of zoledronic acid in early-stage breast cancer.

Main Methods:

  • Analysis of data from three clinical trials (ABCG-12, Z-FAST, ZO-FAST).
  • Assessment of zoledronic acid's impact on bone mineral density in patients receiving standard adjuvant endocrine therapy.
  • Evaluation of zoledronic acid's effects in both premenopausal and postmenopausal hormone receptor-positive breast cancer patients.

Main Results:

  • Twice-yearly zoledronic acid administration prevented cancer treatment-induced bone loss.
  • The drug was effective in both premenopausal and postmenopausal women with hormone receptor-positive breast cancer.
  • Emerging evidence suggests potential anticancer effects in estrogen-deprived settings.

Conclusions:

  • Zoledronic acid is effective in preserving bone mineral density during adjuvant endocrine therapy for breast cancer.
  • Zoledronic acid may offer additional anticancer benefits in specific breast cancer contexts.
  • Long-term safety and side effects necessitate careful consideration in treatment decisions.

More Related Videos

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery11:49

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

Published on: April 3, 2026

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...